Subscribe to receive 91outcomes email updates

Tuesday, February 28, 2017

CDMRP-Funded Study Tests Potential Treatment to Combat Gulf War Illness

This new study was funded by the treatment-focused Gulf War Illness Research Program (GWIRP), part of the Congressionally Directed Medical Research Program (CDMRP) funded by Congress within the U.S. Department of Defense.


SOURCE:  ScienceDaily, by the University of Georgia, Feb. 27, 2017

https://www.sciencedaily.com/releases/2017/02/170227152205.htm



ARCHIVED ARTICLE:


ScienceDaily
Your source for the latest research news

New study tests potential treatment to combat Gulf War Illness

Date:
February 27, 2017
Source:
University of Georgia
Summary:
An estimated 25 percent of the 700,000 troops who engaged in the fierce battles of Operation Desert Storm and related Gulf War combat during 1990-91 are fighting a different, but relentless foe: Gulf War illness. A new study tests potential treatment to combat Gulf War illness.
Share:


Nick Filipov is an associate professor in the department of physiology and pharmacology in the University of Georgia's College of Veterinary Medicine.
Credit: Amy Ware
An estimated 25 percent of the 700,000 troops who engaged in the fierce battles of Operation Desert Storm and related Gulf War combat during 1990-91 are fighting a different, but relentless foe: Gulf War illness.
"Substantial cognitive, learning and motor deficits are among the most profound and debilitating effects of Gulf War illness," said Nick Filipov, associate professor in the department of physiology and pharmacology in the University of Georgia's College of Veterinary Medicine. Other symptoms include extensive pain, headache, fatigue, breathing problems, gastrointestinal issues and skin abnormalities.
While there is some debate on Gulf War illness's causes, research indicates that soldiers participating in the war experienced unprecedented exposures to pesticides, nerve-agents and other chemicals, which combined with the stresses of war, are likely to blame for the illness.
But, said Filipov, "The most pressing issue is that veterans with Gulf War illness are growing older, so the cognitive symptoms will be amplified as age takes a toll on the brain."
Now, funded by a $750,000 grant from the U.S. Department of Defense, Filipov and colleagues are testing a potential treatment that may allow these veterans to fight back.
"A major research interest of mine is how the brain and the immune system function and malfunction in health and disease," said Filipov, who also studies Parkinson's and other neurological diseases with ties to environmental contaminants. "There's increasing evidence that the immune system is dysfunctional in the veterans with Gulf War illness, and perhaps neuroinflammation plays an important part in the manifestations of the disease."
Other members of the research team include John Wagner, professor in the department of physiology and pharmacology, and Don Harn, professor in the department of infectious diseases.
The researchers will administer a novel sugar-based molecule developed by Harn to mice with exposures similar to those of veterans with Gulf War illness. This molecule, which is likely safe because it's found in human milk, has already been tested in a disease model for multiple sclerosis. The investigators expect to reduce or improve Gulf War illness-associated cognitive decline by restoring the immune system's function and mitigating inflammation in the brain.
The study will look at two established models of Gulf War illness: one that involves timed exposures to a pesticide and the anti-nerve gas medication given to Gulf troops, and a second model that incorporates exposure to a nerve gas surrogate, the chemical insect repellent DEET, and stress, in addition to the same exposures as the first group. The researchers will analyze the exposures' immediate effects and administer treatment several months after all exposures have ended.
"Just as Gulf War veterans are being treated for their illness years after they were exposed to chemicals during the war, the mice in our study will experience a delay before they are treated," Filipov said.
The researchers will assess the treatment's effectiveness in improving brain function and restoring the immune system through behavioral, cellular and molecular testing. Results are expected in approximately two years.

Story Source:
Materials provided by University of Georgia. Original written by Elizabeth Fite. Note: Content may be edited for style and length.

Cite This Page:
University of Georgia. "New study tests potential treatment to combat Gulf War Illness." ScienceDaily. ScienceDaily, 27 February 2017. <www.sciencedaily.com/releases/2017/02/170227152205.htm>.

Monday, February 13, 2017

GWI Treatment Development Study Seeking Gulf War veterans in Florida

A Gulf War Illness treatment development research study in Sarasota, Florida, is seeking 1991 Gulf War (Desert Storm) veterans to participate.

The study takes only three to four hours in a single visit to complete, and nominal compensation of $35 is provided to study subjects who complete the short study.



Interested Gulf War veterans should call the phone number listed on the flyer above, or may email Lois Davis at the Roskamp Institute at ldavis@roskampinstitute.net.  

This project is funded by the treatment-focused Gulf War Illness Research Program (GWIRP), part of the Congressionally Directed Medical Research Programs (CDMRP) funded under Defense Health programs.  More information about this project, funded in Fiscal Year 2015 (FY15), is available at:  http://cdmrp.army.mil/search.aspx?LOG_NO=GW150056.

This project builds on an earlier, FY13 GWIRP-funded project, more information about which is available at:  http://cdmrp.army.mil/search.aspx?LOG_NO=GW130045

This project is in collaboration with the GWIRP-funded Gulf War Illness Consortium at Boston University.  More information about the GWIC is available at:  http://sites.bu.edu/gwic/   The GWIC is currently recruiting both healthy 1991 Gulf War veterans and 1991 Gulf War veterans with Gulf War Illness at project sites in Boston, Miami, and Houston.